Decreased availability of nitric oxide and hydrogen sulfide is a hallmark of COVID-19

Hendren, 2020, Description and proposed management of the acute COVID-19 cardiovascular syndrome, Circulation, 141, 1903, 10.1161/CIRCULATIONAHA.120.047349 Nishiga, 2020, COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives, Nat. Rev. Cardiol., 17, 543, 10.1038/s41569-020-0413-9 Bhaskar, 2020, Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper, Front. Immunol., 11, 1648, 10.3389/fimmu.2020.01648 Magro, 2020, Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl. Res., 220, 1, 10.1016/j.trsl.2020.04.007 Potus, 2020, Novel insights on the pulmonary vascular consequences of COVID-19, Am. J. Physiol. Lung Cell Mol. Physiol., 319, L277, 10.1152/ajplung.00195.2020 Varga, 2020, Endothelial cell infection and endotheliitis in COVID-19, Lancet, 395, 1417, 10.1016/S0140-6736(20)30937-5 Kolluru, 2017, Gasotransmitter heterocellular signaling, Antioxidants Redox Signal., 26, 936, 10.1089/ars.2016.6909 Rajendran, 2019, Nitric oxide and hydrogen sulfide regulation of ischemic vascular growth and remodeling, Comp. Physiol., 9, 1213, 10.1002/cphy.c180026 Akaberi, 2020, Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro, Redox Biol, 37, 101734, 10.1016/j.redox.2020.101734 Chen, 2004, Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing, Clin. Infect. Dis., 39, 1531, 10.1086/425357 Citi, 2020, Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H2 S donors in COVID-19 therapy, Br. J. Pharmacol., 177, 4931, 10.1111/bph.15230 Dattilo, 2020, The role of host defences in Covid 19 and treatments thereof, Mol Med, 26, 90, 10.1186/s10020-020-00216-9 Renieris, 2020, Serum hydrogen sulfide and outcome association in pneumonia by the SARS-CoV-2 coronavirus, Shock, 54, 633, 10.1097/SHK.0000000000001562 Yang, 2020, H2S as a potential defense against COVID-19?, Am. J. Physiol. Cell Physiol., 319, C244, 10.1152/ajpcell.00187.2020 Kolluru, 2015, H2S regulation of nitric oxide metabolism, Methods Enzymol., 554, 271, 10.1016/bs.mie.2014.11.040 Rajpal, 2018, Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease, Redox Biol, 15, 480, 10.1016/j.redox.2018.01.007 Chen, 2020, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, 368, m1091, 10.1136/bmj.m1091 Akaike, 2000, Nitric oxide and virus infection, Immunology, 101, 300, 10.1046/j.1365-2567.2000.00142.x Bazhanov, 2017, Hydrogen sulfide: a novel player in airway development, pathophysiology of respiratory diseases, and antiviral defenses, Am. J. Respir. Cell Mol. Biol., 57, 403, 10.1165/rcmb.2017-0114TR Swiatkowska, 2000, Dual regulatory effects of nitric oxide on plasminogen activator inhibitor type 1 expression in endothelial cells, Eur. J. Biochem., 267, 1001, 10.1046/j.1432-1327.2000.01086.x Emerson, 2015, Hydrogen sulfide and platelets: a possible role in thrombosis, Handb. Exp. Pharmacol., 230, 153, 10.1007/978-3-319-18144-8_7 Evgen'ev, 2020, Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia, Cell Stress Chaperones, 25, 713, 10.1007/s12192-020-01120-1 Alamdari, 2020, Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial, Eur. J. Pharmacol., 885, 173494, 10.1016/j.ejphar.2020.173494 Sim, 2010, Nitric oxide and pulmonary hypertension, Korean J Anesthesiol, 58, 4, 10.4097/kjae.2010.58.1.4 Akerstrom, 2009, Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected, Virology, 395, 1, 10.1016/j.virol.2009.09.007 Akerstrom, 2005, Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus, J. Virol., 79, 1966, 10.1128/JVI.79.3.1966-1969.2005 Ozdemir, 2020, Could the decrease in the endothelial nitric oxide (NO) production and NO bioavailability be the crucial cause of COVID-19 related deaths?, Med. Hypotheses, 144, 109970, 10.1016/j.mehy.2020.109970 Alvarez, 2020, Home nitric oxide therapy for COVID-19, Am. J. Respir. Crit. Care Med., 202, 16, 10.1164/rccm.202005-1906ED Wang, 2012, Physiological implications of hydrogen sulfide: a whiff exploration that blossomed, Physiol. Rev., 92, 791, 10.1152/physrev.00017.2011 Kolluru, 2020, Reactive sulfur species: a new redox player in cardiovascular pathophysiology, Arterioscler. Thromb. Vasc. Biol., 40, 874, 10.1161/ATVBAHA.120.314084 Yang, 2020, H2S as a potential defense against COVID-19?, Am. J. Physiol. Cell Physiol., 319, C244, 10.1152/ajpcell.00187.2020 Kolluru, 2013, A tale of two gases: NO and H2S, foes or friends for life?, Redox Biol, 1, 313, 10.1016/j.redox.2013.05.001 Lo Faro, 2014, Hydrogen sulfide and nitric oxide interactions in inflammation, Nitric Oxide, 41, 38, 10.1016/j.niox.2014.05.014 Oh, 2006, Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide, Free Radic. Biol. Med., 41, 106, 10.1016/j.freeradbiomed.2006.03.021 Saini, 2020, Hydrogen sulfide stimulates Mycobacterium tuberculosis respiration, growth and pathogenesis, Nat. Commun., 11, 557, 10.1038/s41467-019-14132-y Williams, 2014, African Americans, hypertension and the renin angiotensin system, World J. Cardiol., 6, 878, 10.4330/wjc.v6.i9.878 Peter, 2013, Plasma free H2S levels are elevated in patients with cardiovascular disease, J Am Heart Assoc, 2, 10.1161/JAHA.113.000387 Watts, 2021, Decreased bioavailability of hydrogen sulfide links vascular endothelium and atrial remodeling in atrial fibrillation, Redox Biology, 38, 101817, 10.1016/j.redox.2020.101817 Malik, 2020, Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis, BMJ Evid Based Med Shishehbor, 2003, Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy, JAMA, 289, 1675, 10.1001/jama.289.13.1675 Fang, 2021, The role of NO in COVID-19 and potential therapeutic strategies, Free Radic. Biol. Med., 163, 10.1016/j.freeradbiomed.2020.12.008 Guan, 2020, Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?, Ageing Res. Rev., 64, 10.1016/j.arr.2020.101201 Harrison, 2020, Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis, PLoS Med., 17, 10.1371/journal.pmed.1003321 Sanyaolu, 2020, Comorbidity and its impact on patients with COVID-19, SN Compr Clin Med, 1 Singh, 2020, Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis, Diabetes Obes. Metabol., 10.1111/dom.14124